Literature DB >> 26246679

Continuing Educational Inertia?

Kyle R Peters.   

Abstract

Year:  2014        PMID： 26246679      PMCID： PMC4521431          DOI： 10.2337/diaclin.32.3.97

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  4 in total

Review 1.  Clinical inertia.

Authors:  L S Phillips; W T Branch; C B Cook; J P Doyle; I M El-Kebbi; D L Gallina; C D Miller; D C Ziemer; C S Barnes
Journal:  Ann Intern Med       Date:  2001-11-06       Impact factor: 25.391

2.  A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

Authors:  Johannes Plank; Manfred Bodenlenz; Frank Sinner; Christoph Magnes; Evelyn Görzer; Werner Regittnig; Lars A Endahl; Eberhard Draeger; Milan Zdravkovic; Thomas R Pieber
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

3.  Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

Authors:  O Klein; J Lynge; L Endahl; B Damholt; L Nosek; T Heise
Journal:  Diabetes Obes Metab       Date:  2007-05       Impact factor: 6.577

4.  Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.

Authors:  A B King
Journal:  Diabetes Obes Metab       Date:  2009-01       Impact factor: 6.577
  4 in total
  1 in total

Review 1.  Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia.

Authors:  Guido Gembillo; Ylenia Ingrasciotta; Salvatore Crisafulli; Nicoletta Luxi; Rossella Siligato; Domenico Santoro; Gianluca Trifirò
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.